For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
To compare the usual treatment alone to using combinations of durvalumab (MEDI4736), olaparib, and cediranib to increase the duration of time that your cancer does not progress.
DiagnosisPatients who have recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer that is resistant to platinum-based chemotherapy and have had prior therapy with bevacizumab.
Platinum resistant ovarian cancer.
At least 2 and up to 5 prior lines of treatment.
Prior use of Bevacizumab required.
Prior PARP/PD-L1 is allowed.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
This study has 4 study groups:
- Group 1: Patients will get one of the usual drugs (standard of care) used to treat your type of cancer.
- Group 2: Patients will receive durvalumab (MEDI4736) plus olaparib and cediranib to treat your cancer.
- Group 3: Patients will receive durvalumab (MEDI4736) plus cediranib to treat your cancer.
- Group 4: Patients will receive olaparib and cediranib to treat your cancer.
For more information, visit ClinicalTrials.gov